Opendata, web and dolomites

NEUREKA SIGNED

A smart, hybrid neural-computo device for drug discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEUREKA project word cloud

Explore the words cloud of the NEUREKA project. It provides you a very rough idea of what is the project "NEUREKA" about.

lack    replication    burden    neurological    repeated    exacerbating    candidates    hybrid    deficits    models    unprecedented    pathological    physiological    exhibiting    shortcoming    mediate    soma    networks    disease    stem    dendritic    human    dysfunction    synaptic    excitability    network    suffers    introduces    failures    proof    neuronal    biological    culture    standard    pathology    synapses    faithfully    registered    drive    pluripotent    drugs    brain    molecular    cell    subcellular    candidate    circuits    reproducing    functions    simulate    ipsc    paradigm    neureka    replicate    drug    effect    computational    cellular    vitro    monitor    axonal    neural    functional    back    akin    fed    alzheimer    cultured    loop    optimize    accuracy    assays    locations    quantification    contact    neurons    incurable    branches    shift    population    neurodegeneration    innovative    whereby    simulated    nanoelectrodes    complementing    multiple    compounds    societal    economical    diseases    discovery    emerge    levels    tree    transmission    closing   

Project "NEUREKA" data sheet

The following table provides information about the project.

Coordinator
IDRYMA TECHNOLOGIAS KAI EREVNAS 

Organization address
address: N PLASTIRA STR 100
city: IRAKLEIO
postcode: 70013
website: www.forth.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 2˙776˙705 €
 EC max contribution 2˙776˙704 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2023-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) coordinator 753˙250.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 756˙452.00
3    MAXWELL BIOSYSTEMS AG CH (ZURICH) participant 466˙562.00
4    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 465˙440.00
5    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) participant 335˙000.00

Map

 Project objective

NEUREKA will bring a paradigm shift in drug discovery for neurological diseases, a sector that suffers multiple, repeated failures exacerbating the economical and societal burden of these incurable diseases. It will do so by addressing a crucial shortcoming: the lack of in vitro systems faithfully reproducing brain pathology that enable the functional assessment of candidate compounds at multiple levels: from synapses to neuronal circuits. NEUREKA introduces an innovative, hybrid technology, whereby detailed, computational neuronal networks simulate dysfunction and drive cultured neurons to replicate in-brain disease conditions. Nanoelectrodes mediate the transmission between simulated and biological neurons. Akin to real synapses, nanoelectrodes contact cultured neurons at subcellular locations across the dendritic tree, soma and axonal branches, allowing to control and monitor neural activity with unprecedented accuracy. Biological neuronal responses registered by nanoelectrodes are fed back to simulated neurons, closing the loop and enabling control of activity states across the hybrid population. Complementing molecular deficits already present in culture models of a disease, computational models enable replication of both molecular and physiological deficits of neurodegeneration in vitro. Cultured neurons are driven towards pathological excitability states where deficits emerge, so as to optimize quantification of the impact of drugs, going well beyond standard cellular assays. A proof-of-concept will be provided for Alzheimer’s disease, using human induced pluripotent stem cell (iPSC)-derived neurons exhibiting the pathology. NEUREKA will be used to demonstrate the effect of drug candidates across synaptic, neuronal and network functions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUREKA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUREKA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

ATEMPGRAD (2019)

Analysing Temperature Effects with a Mobile and Precise Gradient Device

Read More  

BioProMarL (2019)

Bio-inspired Protection of Marble with Lasers

Read More  

CLASSY (2019)

Cell-Like ‘Molecular Assembly Lines’ of Programmable Reaction Sequences as Game-Changers in Chemical Synthesis

Read More